Company Overview and News

86
Major Biopharma Catalysts on July’s FDA Calendar

2018-07-07 247wallst
Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside.
CBIO TBPH NBIX GSK ZYNE ABBV GSK ABBV DRRX PGNX

5
The 3 Safest Dividend Stocks for International Exposure

2018-07-06 investorplace
In any long-term diversified portfolio, international stocks not only have a place, they should be represented by as much as 10% to 15% of your investment.
UL GSK DEO

5
PFE vs. GSK: Which Stock Is the Better Value Option?

2018-07-04 zacks
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE - Free Report) and GlaxoSmithKline (GSK - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
BLT BHP BHPBF BBL GSK BHP BHPLF PFE GSK

4
PRESS DIGEST- British Business - July 4

2018-07-03 reuters
July 4 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
SHI WPPGF RYAOF CIOIF WPPGY GSK RYAAY GSK CIOIY

22
Zafgen Update: After Financing, Continued Revaluation Ahead

2018-07-03 seekingalpha
Second generation MetAP2 inhibitor ZGN-1061 is showing desired efficacy without the safety issues of its predecessor.
ZFGN GSK

4
Liquidia Technologies Starts IPO Process

2018-07-03 seekingalpha
The firm is advancing a pipeline of drug treatments using its PRINT dry inhaled technology portfolio.
GSK GSK

17
WeDoctor, a $6 billion China startup, wants to be the Amazon of health care

2018-07-03 livemint
Hong Kong: As soon as you’re diagnosed as diabetic, ads for treatments show up on social feeds. You get alerts on health supplements, maybe nutrition tips. Prompts on insurance policies pop up on your phone.
0017 SFOSF BABA NWSGY 0659 0700 AAGIY GSK BIDU GSK NWSZF AAIGF

85
4 Drug and Biotech Stocks Awaiting FDA Decisions in July

2018-07-02 investorplace
We are into the second half of the year. It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. The regulatory body approved 17 novel drugs in the first half of 2018, which is less than the year-ago period figure of 23. However, with several FDA decision lined up for the second half, a higher number of drugs could be approved in the rest of the year.
VRTX AMGN JNJ INSY GSK PGNX

46
Novartis to Spin-Off Alcon as Separate Trading Company

2018-07-02 zacks
Novartis AG (NVS - Free Report) announced that it intends to spinoff its ophthalmology division, Alcon, into a separately-traded standalone company in order to grow as a medicines company solely.
WFC WFCNP WFC.WS GILD WFC.PRL WFC.PRJ GSK ONCE WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN NVS GSK WFC.PRY WFC.PRX WFC.PRW WFC.PRV

124
Liquidia To File IPO - What Investors Need To Know

2018-07-02 seekingalpha
Liquidia Technologies (LQDA), has filed the necessary paperwork with the SEC to make an initial public offering. The biopharma company is seeking to raise at least $57 million and will trade on the NASDAQ Capital Market. Jefferies and Cowen will run the book on the IPO.
MNKD ARNA GSK HRTX AERI UTHR INSM ALIOY GSK DRRX

23
New Strong Sell Stocks for July 2nd

2018-07-02 zacks
Axalta Coating Systems Ltd. (AXTA - Free Report) is a manufacturer of high-performance coatings. The Zacks Consensus Estimate for its current year earnings has been revised 0.8% downward over the last 30 days.
MG MDPEB AXTA GSK DXC.WI MDP GSK DXC

7
Novartis: Preparing For More Drug Development

2018-06-29 seekingalpha
So we finally have clarification on Novartis' (NVS) Alcon eye care unit. It is going to be spun off as a separate entity which will trade on the Swiss stock exchange. The unit will be run by David Endicott and he will report to Novartis CEO Vas Narasimhan starting this Sunday. This is good news for Novartis shareholders for a number of reasons.
NVS GSK

65
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale

2018-06-29 zacks
Sanofi (SNY - Free Report) announced that it has finalized its negotiations with private equity firm, Advent International to sell Zentiva, Sanofi’s generic business unit in Europe. The companies have signed a share purchase agreement worth $2.2 billion (1.9 billion euros).
CELGZ CELG NVS GSK PII GSK SNY

70
Will a Trade War With China Wreak Havoc in US Healthcare?

2018-06-29 zacks
Ever since President Trump’s imposition of tariffs on steel and aluminum imports from China, markets at large have suffered dearly. There have been a number of meetings between trade representatives from both the countries but all in vain.
GSK ABBV PII GSK ABBV

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

11h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to GSK / GlaxoSmithKline plc on message board site Silicon Investor.

After Glaxou0027s genital herpes vaccine flop, check out Agenus SI Pigskin Pick em
FOOTBALL: 1999 Pigskin Prognostication Contest TGSK - Great White Marine u0026 Recreation, Inc.
FOOTBALL: 1998 Pigskin Prognostication Contest
CUSIP: 37733W105